{
    "clinical_study": {
        "@rank": "8063", 
        "arm_group": {
            "arm_group_label": "Adjuvanted Trivalent Influenza Virus Vaccine", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety of a single intramuscular (IM) injection of  trivalent adjuvanted\n      influenza study vaccine, formulation 2012/2013, in elderly subjects and the antibody\n      response to each influenza vaccine antigen, as measured by single radial hemolysis (SRH) and\n      hemagglutination inhibition (HI) at approximately 21 days postimmunization in elderly\n      subjects in compliance with the requirements of the current EU recommendations for clinical\n      trials related to yearly licensing of influenza vaccines."
        }, 
        "brief_title": "Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Subjects \u226565 years of age who received one aTIV vaccination", 
                        "title": "\u226565 Y"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "63"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "3.9", 
                                            "@value": "70.5"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "28"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "35"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Subjects"
                        }
                    ]
                }, 
                "population": "Baseline analysis was performed on all enrolled subjects."
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Immunogenicity was measured as the percentage of subjects who achieved seroconversion or significant increase in single radial hemolysis  (SRH) area, against each of three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay.\nSeroconversion or significant increase in SRH area was defined as the percentage of subjects with a negative prevaccination serum (SRH area \u22644 mm2) to a postvaccination SRH area \u226525 mm2; or a significant increase in antibody titer from a non-negative prevaccination serum, i.e., at least a 50% increase in area.\nThe European (CHMP) criterion is met if percentage of subjects achieving seroconversion or significant increase in SRH area is 30% (\u226565 years).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects \u226565 years of age who received one aTIV vaccination", 
                                "title": "\u226565 Y"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "63"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "46", 
                                                        "@upper_limit": "71", 
                                                        "@value": "59"
                                                    }
                                                }, 
                                                "sub_title": "A/H1N1"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "52", 
                                                        "@upper_limit": "77", 
                                                        "@value": "65"
                                                    }
                                                }, 
                                                "sub_title": "A/H3N2"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "69", 
                                                        "@upper_limit": "90", 
                                                        "@value": "81"
                                                    }
                                                }, 
                                                "sub_title": "B"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was measured as the percentage of subjects who achieved seroconversion or significant increase in single radial hemolysis  (SRH) area, against each of three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay.\nSeroconversion or significant increase in SRH area was defined as the percentage of subjects with a negative prevaccination serum (SRH area \u22644 mm2) to a postvaccination SRH area \u226525 mm2; or a significant increase in antibody titer from a non-negative prevaccination serum, i.e., at least a 50% increase in area.\nThe European (CHMP) criterion is met if percentage of subjects achieving seroconversion or significant increase in SRH area is 30% (\u226565 years).", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                                    "units": "Percentages of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the per-protocol (PP) set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22", 
                        "title": "Percentages of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination SRH geometric mean areas (GMAs), directed against each of three vaccine strains, three weeks after vaccination (day 22).\nThe CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is >2.0 (\u226565 years).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects \u226565 years of age who received one aTIV vaccination", 
                                "title": "\u226565 Y"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "63"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "1.93", 
                                                        "@upper_limit": "3.12", 
                                                        "@value": "2.46"
                                                    }
                                                }, 
                                                "sub_title": "A/H1N1"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "2.15", 
                                                        "@upper_limit": "3.35", 
                                                        "@value": "2.68"
                                                    }
                                                }, 
                                                "sub_title": "A/H3N2"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "3.53", 
                                                        "@upper_limit": "5.58", 
                                                        "@value": "4.44"
                                                    }
                                                }, 
                                                "sub_title": "B"
                                            }
                                        ]
                                    }, 
                                    "description": "Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination SRH geometric mean areas (GMAs), directed against each of three vaccine strains, three weeks after vaccination (day 22).\nThe CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is >2.0 (\u226565 years).", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Geometric Mean Ratio of Subjects Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                                    "units": "Ratio"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the PP set.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 22", 
                        "title": "Geometric Mean Ratio of Subjects Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Immunogenicity was measured as the percentage of subjects achieving SRH area \u226525 mm2 against each of three vaccine strains at baseline (day 1) and three weeks after aTIV vaccination (day 22).\nThis criterion is met according to CHMP guideline if percentage of subjects achieving SRH area \u226525 mm2 is 60% (\u226565 years).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects \u226565 years of age who received one aTIV vaccination", 
                                "title": "\u226565 Y"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "63"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "42", 
                                                        "@upper_limit": "68", 
                                                        "@value": "56"
                                                    }
                                                }, 
                                                "sub_title": "A/H1N1 (Day 1)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "89", 
                                                        "@upper_limit": "100", 
                                                        "@value": "97"
                                                    }
                                                }, 
                                                "sub_title": "A/H1N1 (Day 22)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "36", 
                                                        "@upper_limit": "62", 
                                                        "@value": "49"
                                                    }
                                                }, 
                                                "sub_title": "A/H3N2 (Day 1)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "85", 
                                                        "@upper_limit": "98", 
                                                        "@value": "94"
                                                    }
                                                }, 
                                                "sub_title": "A/H3N2 (Day 22)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "10", 
                                                        "@upper_limit": "31", 
                                                        "@value": "19"
                                                    }
                                                }, 
                                                "sub_title": "B (Day 1)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "77", 
                                                        "@upper_limit": "94", 
                                                        "@value": "87"
                                                    }
                                                }, 
                                                "sub_title": "B (Day 22)"
                                            }
                                        ]
                                    }, 
                                    "description": "Immunogenicity was measured as the percentage of subjects achieving SRH area \u226525 mm2 against each of three vaccine strains at baseline (day 1) and three weeks after aTIV vaccination (day 22).\nThis criterion is met according to CHMP guideline if percentage of subjects achieving SRH area \u226525 mm2 is 60% (\u226565 years).", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentages of Subjects Who Achieved SRH Area \u226525 mm2 Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                                    "units": "Percentages of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the PP set.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 1 and 22", 
                        "title": "Percentages of Subjects Who Achieved SRH Area \u226525 mm2 Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 up to and including day 4 after the aTIV vaccination.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects \u226565 years of age who received one aTIV vaccination", 
                                "title": "\u226565 Y"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "63"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "Injection site ecchymosis"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "7"
                                                    }
                                                }, 
                                                "sub_title": "Injection site erythema"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }
                                                }, 
                                                "sub_title": "Injection site induration"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "4"
                                                    }
                                                }, 
                                                "sub_title": "Injection site swelling"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "22"
                                                    }
                                                }, 
                                                "sub_title": "Injection site pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Chills/shivering"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "Malaise"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Myalgia"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Arthralgia"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "4"
                                                    }
                                                }, 
                                                "sub_title": "Headache"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Sweating (N=62)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }
                                                }, 
                                                "sub_title": "Fatigue (N=62)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Fever (\u226538\u00b0C)"
                                            }
                                        ]
                                    }, 
                                    "description": "Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 up to and including day 4 after the aTIV vaccination.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 \u2013 Day 4 Postvaccination)", 
                                    "units": "Number of subjects"
                                }
                            ]
                        }, 
                        "population": "Analysis was done on the safety dataset i.e. the subjects in the exposed population who provided postvaccination safety data.", 
                        "safety_issue": "Yes", 
                        "time_frame": "From day 1 through day 4 postvaccination", 
                        "title": "Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 \u2013 Day 4 Postvaccination)", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Subjects \u226565 years of age who received one aTIV vaccination", 
                        "title": "\u226565 Y"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "63", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "63", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "All enrolled subjects were included in the trial.", 
                "recruitment_details": "Subjects were enrolled at one study center in Belgium."
            }, 
            "point_of_contact": {
                "email": "RegistryContactVaccinesUS@novartis.com", 
                "name_or_title": "Posting Director", 
                "organization": "Novartis Vaccines and Diagnostics"
            }, 
            "reported_events": {
                "desc": "Serious adverse events (SAEs) were collected from day 1 through day 22.", 
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Subjects \u226565 years of age who received one aTIV vaccination", 
                        "title": "\u226565 Y"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "28", 
                                            "@subjects_at_risk": "63"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "22", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "22", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Injection site pain"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "7", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Injection site erythema"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "6", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Injection site induration"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "6", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Fatigue"
                                        }, 
                                        {
                                            "assessment": "Systematic Assessment", 
                                            "counts": {
                                                "@events": "4", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "63"
                                            }, 
                                            "sub_title": "Injection site swelling"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "assessment": "Systematic Assessment", 
                                        "counts": {
                                            "@events": "4", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "4", 
                                            "@subjects_at_risk": "63"
                                        }, 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA", 
                    "frequency_threshold": "5"
                }, 
                "time_frame": "From day 1 through day 22."
            }
        }, 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Human Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female volunteers of 65 years of age or older, mentally competent, willing\n             and able to give written informed consent prior to study entry;\n\n          2. Individuals able to comply with all the study requirements;\n\n          3. Individuals in good health as determined by the outcome of medical history, physical\n             examination and clinical judgment of the investigator.\n\n        Exclusion Criteria:\n\n          1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in\n             the opinion of the investigator, could interfere with the subject's ability to\n             participate in the study.\n\n          2. Individuals with any serious chronic or acute disease (in the judgment of the\n             investigator), including but not limited to:\n\n               -  Medically significant cancer (except for benign or localized skin cancer, cancer\n                  in remission for \u226510 years or localized prostate cancer that has been clinically\n                  stable for more than 2 years without treatment);\n\n               -  Medically significant advanced congestive heart failure (ie. NYHA class III and\n                  IV);\n\n               -  Chronic obstructive pulmonary disease (COPD; i.e., GOLD Stage III and IV);\n\n               -  Autoimmune disease (including rheumatoid arthritis, except for Hashimoto's\n                  thyroiditis that has been clinically stable for \u2265 5 years);\n\n               -  Diabetes mellitus type I;\n\n               -  Poorly controlled diabetes mellitus type II;\n\n               -  Advanced arteriosclerotic disease;\n\n               -  History of underlying medical condition such as major congenital abnormalities\n                  requiring surgery, chronic treatment, or associated with developmental delay\n                  (e.g., Down's syndrome);\n\n               -  Acute or progressive hepatic disease;\n\n               -  Acute or progressive renal disease;\n\n               -  Severe neurological (es. Guillain-Barr\u00e9 syndrome) or psychiatric disorder;\n\n               -  Severe asthma.\n\n          3. Individuals with history of any anaphylactic reaction and/or serious allergic\n             reaction following a vaccination, a proven hypersensitivity to any component of the\n             study vaccine (e.g. to eggs or eggs product as well as ovalbumin, chicken protein,\n             chicken feathers, influenza viral protein, kanamycin and neomycin sulphate).\n\n          4. Individuals with known or suspected (or have a high risk of developing)\n             impairment/alteration of immune function (excluding that normally associated with\n             advanced age) resulting, for example, from:\n\n               -  Receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or\n                  cancer chemotherapy/radiotherapy) within the past 60 days and for the full\n                  length of the study;\n\n               -  Receipt of immunostimulants;\n\n               -  Receipt of parenteral immunoglobulin preparation, blood products and/or plasma\n                  derivates within the past 3 months and for the full length of the study;\n\n               -  Suspected or known HIV infection or HIV-related disease.\n\n          5. Individuals with known or suspected history of drug or alcohol abuse.\n\n          6. Individuals with a bleeding diathesis or conditions associated with prolonged\n             bleeding time that in the investigator's opinion would interfere with the safety of\n             the subject.\n\n          7. Individuals who were not able to comprehend and to follow all required study\n             procedures for the whole period of the study.\n\n          8. Individuals with history or any illness that, in the opinion of the investigator,\n             pose additional risk to the subjects due to participation in the study.\n\n          9. Individuals who within the past 6 months have:\n\n               -  had any laboratory confirmed seasonal or pandemic influenza disease;\n\n               -  received any seasonal or pandemic influenza vaccine.\n\n         10. Individuals who received any other vaccine within 4 weeks prior to enrollment in this\n             study or who are planning to receive any vaccine during the study.\n\n         11. Individuals with any acute or chronic infections requiring systemic antibiotic\n             treatment or antiviral therapy within the last 7 days.\n\n         12. Individuals that have experienced fever (i.e., axillary temperature \u226538\u00b0C) within the\n             last 3 days of intended study vaccination.\n\n         13. Individuals participating in any clinical trial with another investigational product\n             4 weeks prior to first study visit or intent to participate in another clinical study\n             at any time during the conduct of this study.\n\n         14. Individuals who were part of study personnel or close family members conducting this\n             study.\n\n         15. BMI >35 kg/m2."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "firstreceived_results_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651104", 
            "org_study_id": "V70_39S", 
            "secondary_id": "2012-000085-38"
        }, 
        "intervention": {
            "arm_group_label": "Adjuvanted Trivalent Influenza Virus Vaccine", 
            "description": "A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.", 
            "intervention_name": "Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Influenza, Trivalent, Adjuvanted, Adjuvant, MF59, MF-59, Fluad, Seasonal", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "De Pintelaan", 
                    "country": "Belgium", 
                    "state": "BE-9000 Ghent", 
                    "zip": "185"
                }, 
                "name": "University Hospital Ghent Center for Vaccinology"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine (Fluad\u00ae), Formulation 2012/2013, When Administered to Elderly Subjects", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines and Diagnostics", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Immunogenicity was measured as the percentage of subjects who achieved seroconversion or significant increase in single radial hemolysis  (SRH) area, against each of three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay.\nSeroconversion or significant increase in SRH area was defined as the percentage of subjects with a negative prevaccination serum (SRH area \u22644 mm2) to a postvaccination SRH area \u226525 mm2; or a significant increase in antibody titer from a non-negative prevaccination serum, i.e., at least a 50% increase in area.\nThe European (CHMP) criterion is met if percentage of subjects achieving seroconversion or significant increase in SRH area is 30% (\u226565 years).", 
                "measure": "Percentages of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "description": "Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination SRH geometric mean areas (GMAs), directed against each of three vaccine strains, three weeks after vaccination (day 22).\nThe CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is >2.0 (\u226565 years).", 
                "measure": "Geometric Mean Ratio of Subjects Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "description": "Immunogenicity was measured as the percentage of subjects achieving SRH area \u226525 mm2 against each of three vaccine strains at baseline (day 1) and three weeks after aTIV vaccination (day 22).\nThis criterion is met according to CHMP guideline if percentage of subjects achieving SRH area \u226525 mm2 is 60% (\u226565 years).", 
                "measure": "Percentages of Subjects Who Achieved SRH Area \u226525 mm2 Against Each of Three Vaccine Strains After One Vaccination of aTIV", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 22"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 up to and including day 4 after the aTIV vaccination.", 
            "measure": "Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 - Day 4 Postvaccination)", 
            "safety_issue": "Yes", 
            "time_frame": "From day 1 through day 4 postvaccination"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}